BLB resistance assays for homozygous mutant rice lines L-5.7(-6), L-15.4(+1) and L-31.12(-3). by Phuong Nguyen Duy (11414117)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Mean value of the longitudinal scaling exponent as a function of the growth rate threshold <i>b</i>_<i>c</i>. by Fabiano L. Ribeiro (4893388)

“…The mean value of decreases drastically as <i>b</i>_<i>c</i> increases. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Estimated marginal means for changes in outcome parameters A, B, C, D. by Benjamin Udoka Nwosu (476930)

<i>In vivo</i> and long-term chaperone activity assessment of wild-type and p.R163C mutant αB-crystallin. by Aref Baharvand (21713886)

RNA Interference in <em>Schistosoma mansoni</em> Schistosomula: Selectivity, Sensitivity and Operation for Larger-Scale Screening by Saša Štefanić (239531)

“…These findings and the operational parameters defined will facilitate larger RNAi screens.</p></div>…”